Skip to main content

Table 2 Risk factors for sepsis

From: Risk factors for infection following prostate biopsy - a case control study

  Cases Controls OR (95 % CI) P value
Number 71 213   
Patient variables
 Age > 65 years 35 (49.3 %) 92 (43.2 %) 1.34 (0.74, 2.40) 0.33
 Hospital employee 5 (7.0 %) 13 (6.1 %) 1.16 (0.41, 3.33) 0.78
 Autoimmune condition 0 (0 %) 10 (4.5 %) Undefined ND
 Immunosuppression 1 (1.4 %) 3 (1.4 %) 1.00 (0.08, 11.93) 1.00
 COPD 2 (2.8 %) 4 (1.9 % 1.50 (0.27, 8.19) 0.64
 Heart valve replacement 3 (4.2 %) 3 (1.4 %) 3.0 (0.61, 14.86) 0.18
 Benign prostate enlargement 14 (19.7 %) 41 (19.2) 1.24 (0.62, 2.43) 0.54
 Diabetes 10 (14.1 %) 23 (10.8 %) 1.35 (0.61, 2.96) 0.46
 Recent travel 13 (18.3 %) 7 (3.2 %) 5.40 (1.61, 18.09) 0.01
 Recent antimicrobial use 7 (9.8 %) 3 (1.4 %) 9.59 (1.97, 46.62) 0.01
 Recent hospitalisation 1 (1.4 %) 0 (0.0 %) Undefined ND
Procedural variables
 Use of FQ prophylaxis 70 (98.6 %) 213 (100.0 %) Undefined ND
 Duration of FQ prophylaxis <7 days 10 (14.1 %) 44 (20.7 %) 1.72 (0.71, 4.20) 0.23
 Use of aminoglycoside prophylaxis 19 (26.8 %) 43 (20.2 %) 1.85 (0.81, 4.24) 0.14
 Use of a penicillin as prophylaxis 19 (26.8 %) 76 (35.7 %) 0.42 (0.18, 0.98) 0.05
 Use of carbapenem as prophylaxis 0 21 (9.8 %) Undefined ND
 Previous biopsy 12 (16.9 %) 36 (16.9 %) 1.29 (0.62, 2.70) 0.50
 Previous biopsy within 3 years 11 (15.5 %) 26 (12.2 %) 1.31 (0.61, 2.83) 0.48
 Urinary catheter 0 (0 %) 0 (0 %) Undefined ND
 Preoperative urine culture 1 (1.4 %) 0 (0 %) Undefined ND
 Use of enema 31 (43.6 %) 110 (51.6 %) 0.71 (0.30, 1.69) 0.44
 Prostate volume >30 mL 53 (74.6 %) 174 (81.7 %) 1.38 (0.64, 2.93) 0.41
 PSA > 4 mmol 55 (77.4 %) 168 (78.8 %) Undefined ND
 Number of biopsy cores >12 46 (64.8 %) 156 (73.2 %) 0.37 (0.14, 0.95) 0.04
 Prostate cancer 42 (59.2 %) 123 (57.7 %) 1.15 (0.63, 2.07) 0.65
  1. ND not done
\